Chi Sheng Pharma & Biotech Co., Ltd Share Price

Equities

4111

TW0004111000

Pharmaceuticals

End-of-day quote Taipei Exchange 23:00:00 13/05/2024 BST 5-day change 1st Jan Change
26 TWD +0.19% Intraday chart for Chi Sheng Pharma & Biotech Co., Ltd +0.78% -2.44%

Financials

Sales 2022 1.14B 35.55M 2.81B Sales 2023 1.06B 32.99M 2.61B Capitalization 1.52B 47.23M 3.74B
Net income 2022 154M 4.79M 379M Net income 2023 68M 2.11M 167M EV / Sales 2022 1.06 x
Net cash position 2022 328M 10.2M 807M Net cash position 2023 258M 8.03M 636M EV / Sales 2023 1.19 x
P/E ratio 2022
10.1 x
P/E ratio 2023
22.2 x
Employees -
Yield 2022
4.43%
Yield 2023
3.75%
Free-Float 76.71%
More Fundamentals * Assessed data
Dynamic Chart
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 day+0.19%
1 week+0.78%
Current month+0.58%
1 month-1.70%
3 months+0.19%
6 months-2.07%
Current year-2.44%
More quotes
1 week
25.80
Extreme 25.8
26.05
1 month
25.55
Extreme 25.55
26.60
Current year
25.30
Extreme 25.3
27.00
1 year
24.35
Extreme 24.35
30.50
3 years
21.60
Extreme 21.6
36.85
5 years
21.00
Extreme 21
36.85
10 years
15.58
Extreme 15.5769
40.48
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17/06/03
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member - 17/06/03
Director/Board Member - 12/06/12
Director/Board Member - 12/06/12
More insiders
Date Price Change Volume
14/05/24 26 +0.19% 57,296
13/05/24 25.95 0.00% 73,931
10/05/24 25.95 0.00% 29,343
09/05/24 25.95 0.00% 46,316
08/05/24 25.95 +0.58% 159,203

End-of-day quote Taipei Exchange, May 13, 2024

More quotes
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
More about the company

Annual profits - Rate of surprise